This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a chance to buy our favourite stocks.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 index has retreated from its highs around 8,300. One reason for that is the government’s narrative that it will need to take tough decisions to rebalance public finances and boost the economy over the long run.

This is in stark contrast to the US where Donald Trump’s re-election on a tax-cutting ticket has seen American stocks surge to new highs. But despite the supportive growth trends that could come from lower taxes, I think US stocks have stretched valuations.

Finding cheap gems on the FTSE 100

The FTSE 100 currently offers good value for investors, with its price-to-earnings (P/E) ratio and dividend yield appearing attractive compared to other major indexes, especially the US. Many blue-chip companies with global operations — not UK-focused operations — are trading at discounted valuations, potentially presenting opportunities for value investors.

However, it’s important to note that not all FTSE 100 companies are diamonds in the rough or hidden gems. The index’s heavy exposure to cyclical sectors like oil, mining, and banking can lead to volatility and unpredictability. Moreover, some companies may be facing structural challenges or operating in low-growth industries, which could limit their potential for significant returns.

Additionally, we’ve got to think about sentiment. The index hasn’t performed overly well since Labour came to power and promised to make tough decisions to get the country back on track. There aren’t many catalysts on the horizon.

As such, I’m taking a careful approach to investing in the FTSE 100, hand-picking some of my favourite stocks that are worthy of more attention and maybe my money.

A focus on pharma

I’m particularly interested in pharma and biotech because I’m inherently interested in the impact these companies can have on our lives. Unlike investing in tobacco, pharma companies can be a force for good — I know not everyone agrees.

Pharma stocks haven’t performed overly well in recent months, anywhere in the world. There are a number of reasons for this including anti-vaxxer Robert F Kennedy’s potential influence over the Trump presidency.

However, I believe GSK (LSE:GSK) is certainly a key stock to watch. It’s been discounted for some time because of the lawsuits relating to Zantac, however 93% of those cases have now been settled.

Now, the stock is sinking again but it appears overlooked and undervalued to me. The company is expected to report earnings of 91p per share this year, and that then rises to 143p in 2025 and 159p in 2026.

In turn, this means a P/E ratio of 15.1 times for 2024, which then falls to 9.5 times in 2025 and 8.6 times in 2026. These are attractive metrics — below the index average — especially when coupled with the 4.4% forward dividend.

I think the beaten-down share price may also reflect concerns about the company’s newly found independence. There’s no recent track record for how well this business can perform without its consumer healthcare division. As a standalone entity it’s something of an unknown.

Personally I’m also buoyed by the fact the stock trades at a 32% discount to the average share price target. For investors with patience, this could be a great opportunity to consider. I’m going to keep a very close eye on this stock.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has no positions in any of the companies mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »